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  39	
Abstract  40	
DNA somatic copy number aberrations (SCNAs) are key drivers in oesophago-41	
gastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating 42	
tumour (ct)DNA can predict treatment outcomes and reveal how SCNAs evolve during 43	
chemotherapy is unknown. We investigated this by low-coverage whole genome sequencing 44	
(lcWGS) of ctDNA from 30 patients with advanced OGA prior to first-line chemotherapy and 45	
on progression. SCNA profiles were detectable pre-treatment in 23/30 (76.7%) patients. The 46	
presence of liver metastases, primary tumour in situ or of oesophageal or junctional tumour 47	
location predicted for a high ctDNA fraction. A low ctDNA concentration associated with 48	
significantly longer overall survival. Neither chromosomal instability metrics nor ploidy 49	
correlated with chemotherapy outcome. Chromosome 2q and 8p gains before treatment 50	
were associated with chemotherapy responses. lcWGS identified all amplifications found by 51	
prior targeted tumour tissue sequencing in cases with detectable ctDNA, as well as finding 52	
additional changes. SCNA profiles changed during chemotherapy, indicating that cancer cell 53	
populations evolved during treatment, however no recurrent SCNA changes were acquired 54	
at progression. Tracking the evolution of OGA cancer cell populations in ctDNA is feasible 55	
during chemotherapy. The observation of genetic evolution warrants investigation in larger 56	
series and with higher resolution techniques to reveal potential genetic predictors of 57	
response and drivers of chemotherapy resistance. The presence of liver metastasis is a 58	
potential biomarker for the selection of patients with high ctDNA content for such studies. 59	
  60	
Introduction 61	
Gastric and oesophageal cancers are a challenging health issue, representing the 62	
third and sixth leading causes of global cancer mortality respectively [1]. Advances have 63	
been made in the genetic characterisation and development of novel targeted agents for the 64	
adenocarcinoma histological subtype, however the outlook for advanced disease remains 65	
poor with median overall survival not extending beyond 12 months in the majority of trials [2]. 66	
Recent large-scale sequencing projects have improved insights into the genomic landscape 67	
of the disease. The 2014 Cancer Genome Atlas (TCGA) analysis described four different 68	
subtypes of gastric cancer, with the most common CIN subtype being characterised by 69	
chromosomal instability, aneuploidy and, in many cases, focal amplification of receptor 70	
tyrosine kinases. The genomes of these cancers harbour multiple DNA somatic copy 71	
number alterations (SCNAs), defined as deviations in the number of whole chromosomes, 72	
chromosome arms or fragments from the normal number of two copies per cell. With the 73	
exception of p53 mutations, which occur in 70-80% of oesophagogastric adenocarcinomas 74	
(OGA) of the CIN subtype, mutations in cancer driver genes are relatively rare in these 75	
cancers and SCNAs are considered the predominant type of genetic driver alterations [3] [4]. 76	
Common SCNAs identified in CIN tumours in these landmark sequencing studies include 77	
amplifications of chromosomal regions harbouring genes encoding for receptor tyrosine 78	
kinases or their ligands such as ERBB2, EGFR and VEGFA; as well as those involved 79	
pathways regulating proliferation (MYC), and cell cycle (CCNE1, CCND1 and CDK6). These 80	
SCNAs have been implicated as key and, in the case of ERBB2/HER2, clinically actionable 81	
drivers in OGA [5] [6]. 82	
The CIN subtype is common among gastric cancers arising proximally from the 83	
oesophagogastric junction or cardia [3] and in oesophageal adenocarcinomas [4]. The  84	
‘genomically stable’ subtype is characterised by few SCNAs and associated with the diffuse 85	
histological subtype of gastric cancer that commonly arises more distally from the stomach 86	
body [3]. The incidence of non-cardia gastric adenocarcinomas is declining in Western 87	
populations, whilst that of junctional and oesophageal adenocarcinomas is increasing [7]. 88	
These tumours are predominantly of the CIN subtype, and thus detection of SCNAs, in 89	
particular the clinically and biologically relevant driver events within these complex profiles, 90	
are important for the ongoing development of new biomarkers and therapies.  91	
SCNAs have traditionally been analysed through microarray-based techniques, 92	
although more recently improved sensitivity for SCNA detection has been achieved through 93	
exome or whole genome sequencing (WGS). However due to cost, long turnaround times 94	
and intensive bioinformatics analysis requirements, such large scale genomics analyses are 95	
often not feasible. Low coverage WGS (lcWGS), using a coverage of only 0.1-0.5x (i.e. 96	
where only 10-50% of the genome is sequenced), has been shown to be sufficient for 97	
reliable detection of SCNAs, with recent data showing superior SCNA calling compared to 98	
older array hybridisation-based standards [8]. Crucially, lcWGS can also be applied to 99	
analyse tumour derived circulating free (cf)DNA extracted from the plasma of cancer 100	
patients [9]. Such liquid biopsies offer clear practical advantages over conventional biopsies, 101	
including the minimally invasive nature of sample acquisition, relative ease of 102	
standardisation of sampling protocols, and the ability to obtain repeated samples over time. 103	
The latter is of particular interest as changes in SCNA profiles over the course of treatment 104	
may shed light on response and resistance mechanisms to existing chemotherapy agents as 105	
well as to novel targeted agents and immunotherapies.  106	
Intratumour heterogeneity is recognised as a major challenge in the delivery of 107	
effective molecular targeted treatment in OGA [10] [11]. Copy number variation of molecular 108	
targets, as assessed in both tumour and cfDNA, has been shown to impact on therapeutic 109	
targeting of ERBB2, FGFR and EGFR, with high level amplifications being associated with 110	
more favourable responses [12] [13] [14]. Application of targeted genomic sequencing to 111	
cfDNA analysis has been shown to allow the detection of mutations which are 112	
heterogeneous within OGA [15] [16]. Such liquid biopsy techniques may also facilitate 113	
tracking of genetic profile changes over time, but this has not been applied to OGAs 114	
undergoing systemic therapy.  115	
We applied lcWGS to cfDNA from 30 patients with advanced OGA to investigate 116	
whether SCNA analysis can predict responses to first-line chemotherapy, and how these 117	
profiles may evolve during chemotherapy treatment. 118	
 119	
Results  120	
The clinical and pathological characteristics of the 30 included patients are 121	
summarized in Table 1. Extracted cfDNA concentrations from plasma samples taken at pre-122	
treatment baseline ranged from 1.37 to 74.04 ng/mL with a median of 8.88 ng/mL. With a 123	
minimum input quantity of 5 ng for lcWGS, sufficient cfDNA was available from all 30 124	
patients. Univariate analysis showed that the presence of the primary tumour in situ was 125	
associated with a significantly increased cfDNA concentration (Table 2, 9.66 vs 4.81 ng/mL; 126	
p=0.0027, Mann Whitney test). The cfDNA concentration was numerically higher in patients 127	
with liver metastases vs. those without liver metastases (10.09 vs 6.80 ng/mL; p=0.1306, 128	
Mann Whitney test), but this was not significant. No other clinical or pathological parameters 129	
were associated with pre-treatment cfDNA concentration.  130	
Table 1: Clinical characteristics of included patients. 131	
Histopathological variable  
Number of Cases: 30  
Anatomic site of primary:  
 
Gastric   
OGJ/ oesophageal 
6 (20%) 
24 (80%) 
Histological subtype: 
 
Intestinal 
Diffuse 
28 (93%) 
2 (7%) 
Clinical stage at presentation: 
  
Locally advanced  
Metastatic 
3 (10%) 
27 (90%) 
HER2 status*:  
 
Positive 
Negative 
6 (20%) 
24 (80%) 
First line chemotherapy: Platinum/fluoropyrimidine doublet  
Doublet+ anthracycline 
Doublet+ trastuzumab 
9 (30%) 
15 (50%) 
6 (20%) 
Metastatic sites:               Liver  
 
Peritoneal  
 
Lung  
 
Number of metastatic organ 
sites: 
Yes 
No 
Yes 
No 
Yes  
No 
0 - 1 
≥ 2 
 16 (53%) 
14 (47%) 
 6 (20%) 
24 (80%) 
8 (27%) 
22 (73%) 
22 (73%) 
8 (27%)                                            
Primary tumour in situ: 
 
Yes 
No 
23 (77%) 
7 (23%) 
CA19-9 secretor:  
 
Yes 
No 
15 (50%) 
15 (50%) 
*defined as HER2 IHC +++ on baseline diagnostic specimen from patient clinical records; 132	
OGJ- Oesophagogastric junction 133	
Sequencing was performed with 100 bp single-end reads and a target of 12 million 134	
reads per sample. The ichorCNA bioinformatics package [17] was used to reconstruct copy 135	
number profiles from sequencing data and to estimate the fraction of cfDNA that was derived 136	
from tumour cells (henceforth denoted as circulating tumour (ct)DNA content). Based on 137	
ichorCNA analysis, 7/30 cases (23.3%) had ctDNA content of zero, leaving 23 cases 138	
(76.7%) in which SCNA analysis could be performed. The seven cases with zero tumour 139	
content included all three tumours that were only locally advanced rather than metastatic in 140	
this cohort (Cases 2, 152, 195). The other four (57.1%) cases with zero tumour content had 141	
metastatic disease involving only a single organ site (Cases 52, 66, 119, 144). The ctDNA 142	
content showed a poor correlation with the total cfDNA concentration in the plasma (Figure 143	
1A, Pearson correlation r2=0.2312), suggesting that the release of ctDNA from tumour cells 144	
and the total amount of cfDNA, which is a mix of DNA from malignant and non-malignant 145	
cells, are largely independent from each other. The presence of the primary tumour in situ 146	
(9.1% vs 0% median ctDNA content, p=0.0046, Mann Whitney test) and the presence of 147	
liver metastases (18.0% vs 7.2% median ctDNA content, p=0.0043, Mann Whitney test) 148	
significantly correlated with higher ctDNA content (Table 2 and Figure 1B). A greater ctDNA 149	
content was also observed in oesophageal and junctional tumours compared to gastric 150	
tumours (9.3% vs 3.3% median ctDNA content, p=0.0103, Mann Whitney test).  151	
Figure 1 (A) No correlation between cfDNA concentration and the tumour-derived cfDNA 152	
fraction in 30 plasma samples from patients with treatment naïve metastatic gastro-153	
oesophageal cancers. (B) Correlation between selected clinical features and ctDNA fraction 154	
(line denotes median; p-value Mann Whitney test). (C) Kaplan Meier survival analyses of pre-155	
treatment samples grouping by high/intermediate/low cfDNA yield ng/mL plasma, (D) 156	
ichorCNA ctDNA fraction, and (E) ctDNA concentration ng/mL plasma (p-values Log-rank 157	
(Mantel-Cox) test). 158	
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Table 2. Correlation of cfDNA concentration, median ichorCNA ctDNA fraction and ctDNA concentration with clinical and laboratory variables (p-values 161	
Mann-Whitney test). 162	
Histopathological variable N Median cfDNA 
concentration 
(ng/mL plasma) 
p-value Median ctDNA 
fraction (%) 
p-value Median ctDNA 
concentration  
(ng/mL plasma) 
p-value 
Primary tumour    
in situ 
Yes 23 9.66 
0.0027 
9.10 
0.0046 
2.14 
<0.0001 
No 7 4.81 0.00 0.00 
Liver metastases 
present 
Yes 16 10.09 
0.1306 
18.01 
0.0043 
2.18 
0.0099 
No 14 6.80 7.23 0.35 
Primary tumour 
anatomic site 
Gastric 6 8.65 
0.8996 
3.33 
0.0103 
0.24 
0.1401 
Non-gastric 24 9.05 9.31 0.84 
No. of metastatic 
organ sites 
0-1 22 8.31 
0.5042 
7.77 
0.1528 
0.47 
0.9814 
≥2 8 1.22 14.47 0.58 
HER2 status 
Positive 6 11.22 
0.3739 
8.81 
0.4595 
2.25 
0.1713 
Negative 24 8.32 8.22 0.47 
CA19-9 secretion 
Yes 15 9.21 
0.9999 
8.10 
0.5640 
0.61 
0.7733 
No 15 8.54 9.02 0.78 
Taken together, copy number profiles could be analysed from cfDNA in 76.7% of 163	
cases and three distinct characteristics (primary tumour in situ, presence of liver metastases 164	
and oesophageal/junctional primary tumour location) associated with high ctDNA content, 165	
with liver metastases showing the highest tumour fraction of 18% (median).  166	
We next investigated whether any pre-treatment cfDNA metrics correlate with overall 167	
survival (OS). Neither the total cfDNA concentration extracted from plasma (Figure 1C), nor 168	
the ctDNA content estimated by ichorCNA (Figure 1D) correlated with overall survival. 169	
However, the absolute ctDNA concentration in the plasma revealed a significant overall 170	
survival (OS) difference (Figure 1E). The third of patients with the lowest absolute ctDNA 171	
concentration (mean 0.09 ng/mL) had a median OS of 19.5 months whereas those with 172	
intermediate (mean 0.92 ng/mL) and high (mean 10.12 ng/mL) absolute ctDNA 173	
concentration had a median OS of 11.3 and 12.8 months, respectively.  174	
We next investigated whether any specific copy number aberrations or chromosomal 175	
instability metrics correlated with subsequent responses to chemotherapy (Figure 2A and B). 176	
The frequency of copy number gains or losses in 13 responders (based on best radiological 177	
response assessment with serial CT scans during treatment) (Figure 2C) was compared to 178	
those in 10 non-responders who had stable or progressive disease as best response (Figure 179	
2D). Frequency plots showed an overall similar appearance in both groups. However, 180	
several chromosomes showed alterations that were unique to the responders (Figure 2E) 181	
and not present in the non-responder group (Figure 2F). Gains of chromosomes 2q and 8p 182	
were the most frequent (>1/3 of cases) unique aberrations observed only among responders 183	
(Figure 2E).  A minimal consistent region of 28 Mb on Chr2q encompassing 182 genes was 184	
observed in five of 13 cases (34, 63, 68, 134 and 207). These 2q gains were in four cases a 185	
single copy number gain relative to ploidy. A 7.5 Mb minimal consistent region on Chr8p 186	
encompassing 17 genes (Supplemental Table) was detected in six cases (34, 45, 68, 99, 187	
143, 183), four of which as multiple copies above ploidy. Of the uniquely gained genes, 188	
MCPH1 (microcephalin) is notable as a key regulator of DNA damage response and a 189	
repressor of human telomerase reverse transcriptase function [18] and gains of MCPH1 190	
have been implicated in increased platinum sensitivity in non-small cell lung cancer [19] 191	
(Figure 2G). Chr8p also harbours GATA4 which is frequently gained or amplified in OGA [4] 192	
[20], but this was located outside the unique region as gains of GATA4 were observed in 193	
both responders and non-responders (Figure 2G). Other uniquely altered regions were less 194	
frequent and hence difficult to assess (Figure 2E). In contrast, only a single loss of a 12 Mb 195	
minimal consistent region encompassing 117 genes on Chr1p in four cases (123, 126, 90 196	
and 158) was unique to the non-responder group (Figure 2F).  197	
Figure 2 (A) Integer copy number profiles (500 kb bins) for pre-treatment samples, grouped 198	
by subsequent response or (B) non-response to treatment. Red= gain, Blue= loss, Black= 199	
ploidy. (C) Frequency plots showing the number of cases that show segment gains (red) or 200	
losses (blue) in the responder and (D) non-responder groups. (E) Frequency plots showing 201	
segment gains and losses that are unique to the responder group or (F) non-responder group. 202	
(G) Frequency of gain (red) and loss (blue) segments of chromosome 8p in the responder 203	
group (top) and non-responder group (bottom). The most frequent region of unique 8p gain is 204	
indicated, bounded by dotted lines. The locations of MCPH1 and GATA4 are delineated with 205	
a blue dashed line. Two additional non-responder cases showed focal amplifications (orange) 206	
of GATA4, which were identified with the 50 kb bin method but not the 500 kb ichorCNA 207	
analysis. 208	
 209	
Figure 3 (A) Association of pre-treatment CIN metrics with subsequent treatment response 210	
by comparing analysis of genomic change relative to ploidy using weighted Genomic 211	
Instability index (wGII), (B) non-ploidy segment number, and (C) ploidy between responder 212	
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and non-responder groups (line denotes median and interquartile range; p-value Mann 213	
Whitney test). (D) Kaplan Meier progression free survival analyses grouping by high/low wGII, 214	
(E) non-ploidy segment number and (F) ploidy. (G) Kaplan Meier overall survival analyses 215	
grouping by high/low wGII, (H) non-ploidy segment number and (I) ploidy. (J) Heatmap 216	
showing focal gene amplifications (50 kb bins) detected by cfDNA lcWGS at pre-treatment 217	
(orange) or by archival target sequencing (purple) in each case. Black dots indicate cases 218	
classed as HER2+ by immunohistochemistry. Green= responder group, blue= stable group, 219	
red= primary progressor group. 220	
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Chromosomal instability (CIN) has been associated with poor outcomes and 222	
treatment responses in several cancer types [21] [22].  We hence assessed whether CIN-223	
metrics including the weighted genomic instability index (wGII) [23] [24]  (Figure 3A), the 224	
number of gained or lost chromosomal segments (Figure 3B) or ploidy (Figure 3C) 225	
associated with responses or could predict survival in our cohort. None of these metrics 226	
showed a significant difference in responders vs. non-responders or an association with 227	
progression-free (Figure 3D-F) or overall survival (Figure 3G-I). Taken together, the 228	
presence of Chr2q and 8p gains in pre-treatment ctDNA showed an association with 229	
chemotherapy responses. In contrast, we could not identify a role of CIN metrics to predict 230	
patient outcomes in OGA.  231	
The ichorCNA analysis divides chromosomes into 500kb large bins to robustly 232	
assess the copy number state of these segments. Focal genomic amplifications are often 233	
narrow [4] (down to a few dozen kbps) and may have been overlooked as a consequence. 234	
Therefore, to further interrogate whether focal amplifications could be detected in the lcWGS 235	
data, we applied a 50kbp bin approach [25]. This revealed narrow high-level amplifications of 236	
several OGA driver genes [3] [4] (Figure 3J). Any of the high level amplifications (EGFR, 237	
ERBB2, KRAS, MET, MYC, MAPK1/ERK2, CCND1 and GATA4) that were observed in two 238	
or more cases were detected in both responders and in non-responders. Several others 239	
were only observed once and were hence too rare to draw any conclusions. Thus, high-level 240	
amplifications detected pre-treatment did not associate with chemotherapy responses.  241	
As part of the FOrMAT clinical trial, archival formalin-fixed paraffin-embedded 242	
diagnostic or resection samples were sequenced with a custom panel targeting 46 genes 243	
that had prognostic or predictive significance, or were potential targets in existing or 244	
upcoming clinical trials [26]. Amplifications of EGFR, CCND1, CDK6, MET, ERBB2, KRAS, 245	
and FBXW7 had been identified in tissue samples from 11 cases (19, 34, 49, 68, 71, 90, 92, 246	
106, 135, 158, 207). No amplifications were observed in nine cases and archival target 247	
sequencing failed in three cases (45, 58, 123). cfDNA lcWGS of pre-treatment plasma re-248	
identified all of the gene amplifications found by archival tumour sequencing in eight cases 249	
(Figure 3J). Compared to tissue sequencing, ctDNA analysis could not detect CDK6 and/or 250	
KRAS amplifications in three cases that had low ctDNA content (Case 19: 9.1%; Case 49: 251	
7.3%; Case 71: 8.1%). Importantly, in seven cases, cfDNA lcWGS identified additional 252	
amplifications of genes that were included in the FOrMAT sequencing panel but for which no 253	
amplification was detected in the archival tissue analysis: Case 85 (MET and ERBB2 254	
amplification in plasma), Case 126 (MET), Case 134 (MET, KRAS), Case 136 (ERBB2), 255	
Case 143 (CDK4), Case 183 (MET) and Case 207 (ERBB2). In addition, cfDNA sequencing 256	
identified 11 amplifications (in nine cases) of genes that were not covered by the FOrMAT 257	
panel, including GATA4, VEGFA and MYC. 258	
Of six cases (45, 71, 85, 92, 106, 136) that had been classified as HER2 positive 259	
based on standard immunohistochemistry testing of archival tissue, cfDNA sequencing 260	
detected ERBB2 amplifications in five cases. Archival tissue sequencing had identified 261	
ERBB2 amplifications in only two of five successfully sequenced cases (Figure 3J). In one 262	
case (71) immunohistochemical (IHC) analysis of archival tissue had identified HER2 263	
positivity but no amplification was detected by either archival tumour sequencing or cfDNA 264	
lcWGS. Three of the ERBB2 amplified cases (85, 92, 136) had concurrent amplifications in 265	
MAPK1, MET, or VEGFA in the cfDNA (Figure 3J).  266	
Table 3. Comparison of ichorCNA estimated ctDNA fraction at pre-treatment and progression 267	
of first line chemotherapy (p-values Mann-Whitney test). 268	
	
 N Median ctDNA fraction (%) p-value 
All paired cases 
Pre-treatment 20 15.18 
0.1567 
Progression 20 8.72 
Initial radiological response 
followed by progression to 
chemotherapy:  
‘primary responders’ 
Pre-treatment 12 17.00 
0.0200 
Progression 12 7.59 
Stable disease or primary 
radiological progression to 
chemotherapy:  
‘primary non-responders’ 
Pre-treatment 8 11.27 
0.7984 
Progression 8 13.58 
269	
 lcWGS was applied to cfDNA collected at the time of radiological progression during 270	
or after first line treatment from 20 patients that had detectable ctDNA pre-treatment profiles 271	
and had a post-treatment sample available. Twelve of these had an initial radiological 272	
response with subsequent disease progression (primary responders). Eight showed stable 273	
disease or primary progression during chemotherapy (primary non-responders). In the 274	
primary responder group, the ichorCNA ctDNA fraction at progression was significantly lower 275	
than at pre-treatment (17% vs 7.6%; p=0.02; Table 3) whereas no significant change was 276	
observed in the primary non-responder group. Only three out of twenty samples taken at 277	
progression had a ctDNA content of zero (Cases 68, 99, 183), showing that ctDNA remains 278	
detectable in the majority of tumours. The copy number profiles of the remaining 17 cases 279	
(Supplemental Figure 1) were assessed for changes over the course of chemotherapy 280	
treatment (Figure 4A). Using the 50 kb bin approach, all focal amplifications present before 281	
treatment were re-identified at progression (data not shown). No new focal amplifications 282	
were identified at progression.  283	
In a second approach, we subtracted the pre-treatment absolute copy number 284	
(generated with ichorCNA) from the absolute copy number in the matched progression 285	
sample to assess which chromosomes changed through chemotherapy. To avoid artefacts 286	
from differences in tumour content, this pairwise comparison was only performed in seven 287	
cases where tumour content was similar and above 10% at both pre-treatment and 288	
progression. Only changes of the integer copy number value exceeding +/-0.8 were 289	
considered to enrich for new aneuploidies that had likely occurred in the majority of cells in 290	
the tumour and to avoid overinterpretation of changes in small subclones. The SCNA profiles 291	
were overall similar before treatment and at progression, but multiple individual segmental 292	
and arm-level changes were observed (Figure 4B). The fraction of the genome that changed 293	
(defined as the percent of the total genomic length that changed) was higher in responders 294	
(median: 5.65%, n=4) than in non-responders (median: 2.6%, n=3, Figure 4B) but this was 295	
not statistically significant. Individual cases showed new gains or losses in multiple 296	
chromosomes. However, most of the genomic regions that changed between pre-treatment 297	
and progression were only observed in a single case, and no large regions were changed in 298	
more than two cases (Figure 4C). 299	
Figure 4 (A) Frequency plots showing the number of cases (n=17) that show segment gains 300	
(red) or losses (blue) at pre-treatment (top) and at progression (bottom). (B) For 7 pairs where 301	
both samples had >10% ctDNA fraction, comparative plots showing absolute copy number 302	
gains and losses at progression relative to pre-treatment, ordered by the extent of genomic 303	
change. The percent genomic change for each sample is indicated to the right of each plot. 304	
Red= gain, Blue= loss, Black= no change. A minimum of 0.8 copy number change was 305	
required to score a gain or a loss. (C) Frequency plot showing the number of cases (n=7) that 306	
show segment gains (red) or losses (blue) at progression relative to pre-treatment.  307	
 308	
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Discussion 311	
Through use of liquid biopsy we successfully analysed the SCNA profiles of 76.7% of 312	
30 advanced OGAs. Serial analysis before and after first line chemotherapy was feasible in 313	
85% of cases (17/20) that had detectable ctDNA prior to treatment. This demonstrates proof-314	
of-concept that lcWGS of cfDNA can reveal genome wide SCNA profiles in the majority of 315	
patients with advanced OGA, for example to investigate novel prognostic or predictive 316	
biomarkers.  317	
We identified several clinical characteristics that should support the selection of 318	
patients with a predictably higher cfDNA analysis success rates in future studies: the 319	
presence of liver metastases was associated with the highest ctDNA concentrations, whilst 320	
the ctDNA concentration was also significantly higher if the primary tumour was in situ. This 321	
may be the result of more aggressive tumours presenting with synchronous metastatic 322	
disease at baseline compared to those with metachronous metastases following resection. 323	
All seven cases with zero ctDNA pre-treatment either only had locally advanced disease or 324	
low metastatic burden. The use of such biomarkers to select OGA patients who are suitable 325	
for cfDNA sequencing may allow prioritizing these for liquid biopsy-based genotyping over 326	
sequencing of OGA tumour tissue, which has had moderate reported success rates due to 327	
technical challenges such as frequent low tumour content in endoscopic biopsies [26] [27]. 328	
With readily assessable clinical characteristics to identify suitable patients, cfDNA analysis 329	
could become the method of choice to assess amplifications for molecular stratification and 330	
particularly to longitudinally investigate SCNA evolution.  331	
Neither pre-treatment total cfDNA concentration nor ctDNA tumour content correlated 332	
with survival, however, a low absolute plasma ctDNA concentration was significantly 333	
associated with better OS. A previous gastric cancer case series has described an 334	
association between baseline cfDNA and both relapse risk and adverse prognosis in the 335	
advanced disease setting [28], however larger studies are needed to validate the clinical 336	
utility of such metrics for optimisation of treatment and surveillance strategies [29]. 337	
High chromosomal instability (CIN) has been linked to poorer prognosis and drug 338	
sensitivity across a range of cancer types and to drug resistance in vitro [22] [30]. Application 339	
of several CIN metrics could not identify a correlation with chemotherapy response or 340	
survival in our cohort. This could indicate that CIN metrics may perform less well when 341	
generated from ctDNA, as this samples a summative copy number profile of the entire 342	
cancer population. Alternatively, these metrics may only weakly correlate with 343	
aggressiveness and treatment sensitivity and specific genetic aberrations, acquired as a 344	
consequence of CIN, may be more relevant in determining the response and outcome of 345	
individual tumours. Although studies of larger cohorts may be able to reveal an association 346	
in the future, our results suggest that analysis of these CIN metrics in ctDNA is unlikely to be 347	
useful to predict individual patient outcomes in unselected patients undergoing first line 348	
chemotherapy. 349	
For patients with evaluable ctDNA, multiple SCNAs could be identified in genes that 350	
are currently clinically relevant, or may become relevant to future practice. In samples with 351	
detectable ctDNA we identified all amplifications that had been found by previous targeted 352	
sequencing of matched FFPE tissue samples [26]. In seven cases, lcWGS found an 353	
additional nine focal amplifications in genes that had been analysed by targeted sequencing 354	
in tissue (ERBB2, MET, KRAS, CDK4) and where no amplification had been called. In three 355	
cases where tumour tissue sequencing failed, amplifications in ERBB2, FGFR2, EGFR, and 356	
CCND1 were identified in ctDNA. Furthermore, lcWGS revealed multiple additional 357	
amplifications of potentially targetable driver genes such as VEGFA, highlighting the 358	
advantage of whole genome approaches over predetermined targeted sequencing gene 359	
sets.  360	
Concurrent pre-treatment amplifications of MAPK1, MET, or VEGFA with ERBB2 361	
were seen in 3/6 HER2 positive cases. These may potentially influence variability of 362	
outcomes to HER2 targeted therapy, as amplifications of MET and MAPK1 have previously 363	
been implicated in trastuzumab resistance [31] [32]. However the limited numbers in this 364	
cohort precluded meaningful survival analyses. 365	
Comparison of pre-treatment SCNA profiles revealed gains of chromosomes 2q and 366	
8p in cases that subsequently responded to treatment, and these gains were absent in non-367	
responders. These need to be investigated in larger cohorts to assess their potential role as 368	
predictive biomarkers. The uniquely gained region on chromosome 8p harbours the DNA 369	
damage regulator MCPH1, which has been suggested to increase sensitivity to platinum 370	
chemotherapy [19]. This is therefore a candidate gene for further investigation. Identifying 371	
predictive biomarkers of chemotherapy response is an unmet need, but has been 372	
challenging; to date, the most extensive study of	 genetic predictors of therapy response 373	
using targeted sequencing of tumour tissue in advanced OGA failed to identify any 374	
biomarkers of response to platinum based chemotherapy [27].  375	
Both ctDNA detection and lcWGS was possible from plasma samples taken at the 376	
timepoint of progression on first line chemotherapy, with 17/20 (85%) cases having 377	
detectable ctDNA. SCNA profiles were relatively stable between the pre-treatment and 378	
progression samples, but segmental and whole chromosomal arm changes were detected in 379	
seven cases where pair-wise comparison was quantifiable. As it is unlikely that multiple 380	
subclones within a cancer would all gain or lose the same chromosomal regions, these copy 381	
number changes suggested that there had been major shifts in the clonal composition of the 382	
tumour cell populations with one or a few subclones becoming dominant whereas others had 383	
been lost. lcWGS may therefore be a useful technology for the investigation of resistance 384	
landscapes in larger cohorts. The lack of recurrent copy number change events at 385	
progression in this study may be a result of the small evaluable cohort, but equally it is 386	
feasible that chemotherapy resistance may be driven by point mutations. Use of a higher 387	
resolution technique that will allow the combined analysis of SCNA and mutations (such as 388	
whole exome cfDNA sequencing) may be warranted, with patient selection based on the 389	
presence of liver metastases to maximise successful sequencing rates and cost efficiency.  390	
Longitudinal cfDNA analysis has become a favoured method to interrogate resistance 391	
mechanisms during treatment, such as the tracking of known oncogenic RAS mutations in 392	
colorectal cancer [33]. Dynamic cfDNA testing should be equally applicable to monitor 393	
resistance to therapy in OGA.  394	
The potential clinical application for this technique lies in the feasibility of biomarker 395	
stratification on the basis of lcWGS cfDNA sequencing, circumventing some of the limitations 396	
related to tumour heterogeneity in OGA [13]. Furthermore, sequential lcWGS of cfDNA is a 397	
low cost method for continuing to investigate genetic changes associated with chemotherapy 398	
response in larger series or for early detection of resistance mechanisms to novel agents in 399	
clinical trials. Preliminary proof of concept for the use of longitudinal cfDNA analysis to 400	
predict response and resistance to HER2-targeting treatment has already been described 401	
[34]: ERBB2 copy number alterations detected by targeted sequencing were found to be 402	
associated with both innate and acquired trastuzumab resistance. Additionally, mutations in 403	
genes including PIK3CA, ERBB2 and ERBB4 were also associated with resistance, 404	
highlighting the benefit of combined mutation identification and SCNA analysis in 405	
interrogating drug resistance mechanisms. Detection of relevant gene amplifications in 406	
cfDNA has been already shown to be clinically important for patient selection and 407	
therapeutic targeting of FGFR in gastric cancer [13]. However, the plasma contains multiple 408	
components in addition to cfDNA that could also be utilised to realise the full potential of the 409	
liquid biopsy. Promising techniques under investigation in OGA include the enumeration and 410	
characterization of circulating tumour cells (CTCs), which has been associated with both 411	
prognosis [35] and treatment response [36]. In prostate cancer, mRNA extracted from CTCs 412	
has been used to identify splice variants of the androgen receptor that are prognostic for 413	
taxane therapy [37]. Furthermore, CTCs from small cell lung cancer have been successfully 414	
cultured ex vivo in order to screen for targeted therapy sensitivity and relevant biomarkers 415	
[38, 39]. As an alternative to CTCs and cell free nucleic acids, exosomes may also provide a 416	
means for tumour profiling, including in OGA [40].  417	
As novel targeted and immune-modulating therapies are introduced into clinical 418	
management of OGA, there will be a need for stratification of patients in order to guide 419	
personalised treatment. The use of genome-wide analysis to interrogate key driver events 420	
and genomic evolution over time will be important in refining the effective biomarker 421	
stratification of such treatments moving forwards. It is possible that a combination of lcWGS 422	
cfDNA sequencing with CTC or exosome analyses will facilitate maximal clinical utility to be 423	
gained from liquid biopsy approaches in order to guide treatment decisions. Ultimately this 424	
may support precision medicine in both trial and routine clinical practice settings by avoiding 425	
the cost, delay and clinical complications of repeated invasive biopsy procedures. 426	
 427	
Methods  428	
Trial design and sample collection 429	
The FOrMAT (Feasibility of a Molecular Characterisation Approach to Treatment, 430	
Chief Investigator: N Starling ClinicalTrials.gov NCT02112357) study enrolled patients with 431	
advanced gastrointestinal malignancies treated at the Royal Marsden from February 2014 to 432	
November 2015 [26]. The trial was approved by the UK National Ethics Committee (approval 433	
number: 13/LO/1274RM) and all patients provided written informed consent. As part of the 434	
tissue collection component of the trial, blood samples were obtained at trial entry and at the 435	
timepoint of response assessment CT scans during treatment. The trial recruited 71 436	
advanced OGA cancer patients in total. The clinical trial database was interrogated to 437	
identify 30 patients with a diagnosis of locally advanced inoperable or metastatic OGA who 438	
had undergone pre-treatment research blood sampling prior to commencement of treatment, 439	
and whom had sequential bloods spanning at least the full course of comparable first-line 440	
systemic chemotherapy, consisting of a platinum/fluoropyrimidine doublet in all cases, plus 441	
or minus anthracyline or, in the case of ERBB2 positive tumours, trastuzumab. cfDNA was 442	
extracted from plasma samples taken at a baseline pre-treatment timepoint for all patients. 443	
To assess the evolution of SCNA through treatment, lcWGS was additionally performed on 444	
cfDNA collected at the time of radiological progression during or after first line platinum and 445	
5FU based combination chemotherapy from 20 patients that had detectable ctDNA pre-446	
treatment profiles and had a post-treatment sample available.   447	
cfDNA extraction and quantification 448	
Plasma was separated within 2 hours of blood draw and frozen at -80C. The QIAamp 449	
Circulating Nucleic Acid Kit (Qiagen) was used to isolate cfDNA from 3-4 mL plasma 450	
according to manufacturer’s instructions. cfDNA within a size range of 100 to 700bp was 451	
quantified using a Bioanalyzer High Sensitivity chip (Agilent), encompassing the 452	
predominant 3 cfDNA fragment peaks [41].  453	
lcWGS 454	
For the majority of cases 10ng of input DNA was used for sequencing, although in 455	
some cases with limited yield, 5ng were used [42]. Libraries were prepared using the 456	
NEBNext Ultra DNA Library Prep kit (NEB), pooled and sequenced on an Illumina 457	
HiSeq2500 in Rapid mode single read 100bp. 458	
SCNA analysis 459	
Sequencing reads were aligned to the human reference genome (hg19) using Bowtie 460	
(v1.2.9) [43] and resultant bam files were deduplicated using Picard MarkDuplicates 461	
(http://picard.sourceforge.net; v.2.1.0). Reads were subsequently assigned to non-462	
overlapping 500 kb bins and normalized to correct for GC-content and mappability bias using 463	
the HMMcopy suite (http://compbio.bccrc.ca/software/hmmcopy/) [44]. IchorCNA [17] was 464	
used to quantify tumour fraction in cfDNA from lcWGS without prior knowledge of SSNV or 465	
SCNAs present in the primary tumour sample. IchorCNA segmented data was normalised 466	
using the best-fit tumour content and ploidy solution in order to compare samples. To 467	
compare multiple samples, data was uniformally segmented using interpolate.pcf, part of the 468	
copynumber package in R (http://bioconductor.org/packages/copynumber/) [45]. Cohort 469	
frequency plots were generated using the copynumber plotFreq function. Seg files were 470	
viewed as a heat map using the Integrated Genome Viewer software (Broad Institute; 471	
v.2.3.97), allowing comparison of genomic SCNA profiles across multiple samples with the 472	
ability to zoom in to areas of interest in order to investigate genes located within this 473	
genomic region [46]. Focal SCNAs were identified by assigning mapped reads to 50kb bins 474	
using the method described by Baslan [25]. SCNAs were assessed in IGV by two 475	
independent observers and recorded for all patients.  476	
Survival analyses by pre-treatment circulating DNA metrics  477	
 Tertile survival analyses were undertaken according to three circulating DNA metrics: 478	
(1) total cfDNA concentration extracted from plasma, (2) ctDNA content estimated by 479	
ichorCNA and (3) absolute ctDNA concentration in the plasma, calculated by multiplying the 480	
total cfDNA concentration with the ichorCNA ctDNA content. In each case the 30 samples 481	
were classified into ‘low’, ‘medium’ and ‘high’ tertiles for each metric and overall survival 482	
trend was analysed using log-rank method. 483	
Data availability 484	
 Sequence reads have been deposited in the European Genome Phenome Archive 485	
(ID: submission ongoing – will be updated as soon as ID assigned). 486	
 487	
Conclusions 488	
SCNA profiles were successfully analysed through the use of lcWGS applied to 489	
cfDNA extracted from pre-treatment baseline plasma samples in 23/30 (76.7%) cases. The 490	
presence of liver metastases, primary tumour in situ and oesophageal or junctional primary 491	
tumour site were associated with higher pre-treatment ctDNA content, and a lower baseline 492	
ctDNA concentration was associated with subsequent improved overall survival. 493	
Concordance was noted with prior targeted tumour sequencing results, and additionally 494	
lcWGS revealed additional amplifications of potentially targetable driver genes, highlighting 495	
the advantage of whole genome approaches over predetermined targeted sequencing gene 496	
sets. ctDNA detection and lcWGS was possible from plasma samples taken at the timepoint 497	
of progression on first line chemotherapy, with SCNA profiles successfully analysed in 17/20 498	
(85%) cases. Although SCNA profiles were relatively stable between pre-treatment and 499	
progression, segmental and whole chromosomal arm changes were detected in seven cases 500	
where pair-wise comparison was quantifiable. Such shifts in the clonal composition of 501	
tumour cell populations during chemotherapy warrant further investigation as a possible 502	
dynamic means of investigating resistance  landscapes in OGA. 503	
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Supplemental Table: Genes in frequently gained region of chromosome 8p in responders 649	
CSMD1 
LOC100287015 
MCPH1 
ANGPT2 
CLDN23 
MFHAS1 
ERI1 
MIR4660 
PPP1R3B 
LOC157273 
TNKS 
MIR597 
LINC00599 
MIR124-1 
MSRA 
PRSS55 
RP1L1 
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  651	
Supplemental Figure 1 Integer copy number profiles for the 17 paired non-zero ctDNA 652	
cases at progression. ichorCNA ctDNA fraction is indicated for each sample. 653	
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